Pharmacokinetics of Testosterone Lotion in the Treatment of Hypogonadal Males

Phase 2CompletedNCT00372008

Acrux DDS Pty Ltd40 enrolled

Overview

Testosterone replacement treatment is the most effective way of treating hypogonadism in men. Acrux has a proprietry testosterone replacement product - Testosterone-MD Lotion, and this study will evaluate the efficacy and safety of this product.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

NONE

Enrollment

Conditions

Hypogonadism

Interventions

TestosteroneDRUG

Eligibility

Sex: MALEMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Hypogonadal males between 18-70 years old with qualifying general medical health Exclusion Criteria: * Disqualifying concurrent conditions or allergy/sensitivity to testosterone replacement therapy

Locations (7)

Birmingham

Birmingham, Alabama, United States

Unnamed facility

La Mesa, California, United States

Unnamed facility

Torrance, California, United States

Unnamed facility

New Britain, Connecticut, United States

Outcomes

Primary Outcomes

Pharmacokinetic

Secondary Outcomes

Safety and tolerability

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.